Niox Group PLC

NIOX Group PLC maintains a strong liquidity position with a current ratio of 3.81, indicating the company can easily cover its short-term liabilities with its current assets. The company's debt-to-equity ratio is 0.01, reflecting a conservative capital structure with minimal leverage. Total liabilities amount to £2.5 million, while total equity stands at £73.7 million, suggesting a strong equity base. Profitability metrics show a return on equity (ROE) of 9.5% and a return on assets (ROA) of 9.19%, both exceeding the typical thresholds for the pharmaceutical industry. The company's operating income of £10.7 million and net income of £7 million indicate strong operational performance. Gross profit of £33.7 million on revenue of £48.7 million suggests efficient cost management and pricing power. The company's geographic exposure is not explicitly detailed in the input data, but it operates in over 50 countries through a direct sales organization and distributor network. Revenue concentration data is not provided, but the extensive distribution network implies a diversified geographic footprint. Growth trajectory is supported by a positive outlook, with operating cash flow of £15.4 million and free cash flow of £4.6 million. Capital expenditures of £1.5 million indicate ongoing investment in operations. The company's revenue of £48.7 million reflects a solid foundation for future growth. Risk factors include a medium liquidity risk, as net cash is negative after subtracting total debt. The dilution risk is low, with no significant dilution potential noted. The company's conservative capital structure and strong equity base mitigate credit risk. Recent events include analyst estimates with a mean price target of £82.00 and a median price target of £82.00. The mean recommendation is 1.60, indicating a strong buy consensus with 2 strong-buy and 3 buy ratings. No hold or sell ratings are reported.